Background The rapidly expanding clinical adaptation of prostate-specific membrane
antigen (PSMA)-targeted PET imaging in the evaluation of patients with prostate cancer has …

In the past decade, a growing body of literature has reported promising results for prostate-
specific membrane antigen (PSMA)-targeted radionuclide imaging and therapy in prostate …

Background Prostate-specific membrane antigen (PSMA) is the up-and-coming target for
molecular imaging of prostate cancer. Despite its name, non-prostate-related PSMA …

Imaging of the prostate-specific membrane antigen (PSMA) has become an important tool
for managing patients with recurrent prostate cancer, and one of the most frequently …

The continuing adoption of prostate specific membrane antigen (PSMA)-targeted PET for
prostate cancer molecular imaging requires imagers and clinicians alike to be aware of the …

The novel Gallium-68 prostate-specific membrane antigen (PSMA)-bis [2-hydroxy-5-
(carboxyethyl) benzyl] ethylenediamine-diacetic acid positron emission tomography (PET) …

In the past 15 years, encouraging clinical results for the detection of small lymph node
metastases was obtained by the use of Combidex‐enhanced MRI (CEM, also known as …

Prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer epithelium,
making it a promising target for molecular imaging and therapy. Recently, several studies …

Aim PSMA (prostate-specific membrane antigen) is physiologically expressed in normal
prostate tissue and over expressed in prostate cancer cells, therefore constituting a potential …

Background Prostate-specific membrane antigen (PSMA) is expressed in the
microvasculature of thyroid cancer. This suggests the potential use of PSMA as a diagnostic …